Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Next Previous
Trial Profile

A Phase 1a, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IBI 110 (Primary) ; Sintilimab (Primary) ; Carboplatin; Paclitaxel
  • Indications Endometrial cancer; Gastric cancer; Liver cancer; Lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Innovent Biologics

Most Recent Events

  • 11 Sep 2024 Results (n=89) assessing safety and efficacy of IBI363 in pts with advanced non-small cell lung cancer (NSCLC),published in Innovent Biologics media release
  • 10 Sep 2024 According to an Innovent Biologics media release, announced the presentation of Phase 1 clinical data for IBI363 in advanced non-small cell lung cancer at the 2024 World Conference on Lung Cancer (WCLC).
  • 14 Jun 2024 Results published in an Innovent Biologics media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top